Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suncoast Research Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$8,357,812

423 payments

Through program year 2025, Suncoast Research Associates LLC is reported as receiving $8,357,812 in research payments, across 423 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,570,581 107
2024 Research $1,844,995 105
2023 Research $2,295,695 93
2022 Research $1,341,379 62
2021 Research $201,859 27
2020 Research $36,434 13
2019 Research $66,869 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $5,486,913 153 payments
  2. Janssen Research & Development, LLC $892,930 34 payments
  3. GlaxoSmithKline, LLC. $532,716 36 payments
  4. Bavarian Nordic A/S $393,107 10 payments
  5. Sanofi US Services Inc. $274,091 17 payments
  6. Novavax Inc $214,808 29 payments
  7. Pfizer Inc. $184,319 58 payments
  8. Moderna TX, Inc. $119,595 24 payments
  9. Merck Sharp & Dohme Corporation $119,319 4 payments
  10. Astellas Pharma Global Development $39,627 29 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older $1,985,113 27 payments
  2. A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts $1,791,579 66 payments
  3. A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older $1,554,225 34 payments
  4. A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years $702,839 20 payments
  5. A Phase III, Randomized, Open-Label, Controlled, Multi-Center Study to $412,384 14 payments
  6. Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years $320,477 7 payments
  7. A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older $190,091 14 payments
  8. A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older $168,965 19 payments
  9. PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years $151,580 3 payments
  10. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age $116,397 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record